| Charlotte Black, CCC-SLP | |
|
4733 Delridge Way Sw, Seattle, WA 98106-1330 | |
| (919) 624-6103 | |
| Not Available |
| Full Name | Charlotte Black |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 4733 Delridge Way Sw, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295500528 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL61503737 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Charlotte Black, CCC-SLP 4733 Delridge Way Sw, Seattle, WA 98106-1330 Ph: () - | Charlotte Black, CCC-SLP 4733 Delridge Way Sw, Seattle, WA 98106-1330 Ph: (919) 624-6103 |
News Archive
Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. The study was published online by JAMA, and is being released to coincide with its presentation at the American College of Cardiology's 65th Annual Scientific Session & Expo.
Today, Lung Cancer Alliance (LCA) proudly announced that The Honorable Michael G. Oxley has agreed to join its Board of Directors. Oxley, a former Member of Congress, joins LCA, the only national organization dedicated solely to all those either living with or at risk for lung cancer, as it prepares to begin its sixth year of patient support and advocacy headquartered in Washington, DC.
A team of researchers in the U.S. have developed a nanoparticle with the ability to precisely deliver cancer-fighting drugs.
Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital. New investors Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital also joined the round. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma.
› Verified 5 days ago
Amy L Donaldson, PH.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Autism Ctr, Box 357920, Seattle, WA 98195 Phone: 206-897-1801 | |
Ms. Carol L Ray, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4507 Sunnyside Ave N, Unit D, Seattle, WA 98103 Phone: 206-849-3937 | |
Ms. Linda E Eblen, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4800 Sand Point Way Ne, Mail Stop W-6839, Seattle, WA 98105 Phone: 206-987-6164 | |
Mrs. Genevieve Houdet-cote, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1100 9th Ave, Ms:h4-pmr, Seattle, WA 98101 Phone: 206-341-0461 | |
Daelene King, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9100 5th Ave Ne, Seattle, WA 98115 Phone: 206-526-2662 | |
Molly Beier, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-744-3000 | |
Vassalo Speech And Language Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2300 W Bertona St, Seattle, WA 98199 Phone: 978-444-0321 |